查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088905

乳癌診斷市場：2026-2032年全球市場預測（按產品、技術、生物標記類型、檢體類型、臨床應用案例和最終用戶分類）

Breast Cancer Diagnostics Market by Offering, Technology, Biomarker Type, Sample Type, Clinical Use Case, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乳癌診斷市場將成長至 115.4 億美元，複合年成長率為 8.03%。

主要市場統計數據
基準年 2025 67.1億美元
預計年份：2026年 72.4億美元
預測年份 2032 115.4億美元
複合年成長率 (%) 8.03%

乳癌的診斷正從孤立的檢測轉向綜合性的、基於風險的診療模式，結合乳房X光篩檢、超音波、磁振切片檢查、活體組織切片、組織病理學檢查、免疫組織化學檢查、基因組檢測和數位病理學檢查。臨床上的迫切性顯而易見。根據世界衛生組織（WHO）統計，2022年全球約有230萬名女性被診斷出罹患乳癌，約67萬人因此死亡，這使得早期發現和準確診斷成為癌症防治的關鍵。

對於行業領導者而言，商機在於早期發現、快速確診和更精準的治療方案選擇。在已建立完善的系統性篩檢、保險報銷、病理檢測能力和腫瘤治療基礎設施的地區，市場需求最為旺盛。診斷準確性、工作流程效率、更高的可近性和實證治療路徑正成為關鍵的競爭優勢。

乳癌診斷的變革性變化

該領域的格局正受到三大結構性變革的重塑：篩檢覆蓋範圍的擴大、精準腫瘤學的發展以及數位技術在診斷中的應用。儘管數位乳房斷層合成技術提高了病灶的可視化效果，但磁振造影（MRI）和超音波在緻密乳房組織、高風險患者以及診斷追蹤中仍然發揮著至關重要的作用。多個國家更新的篩檢指南也更加重視風險分層、乳房密度以及異常觀察後的及時診斷檢測。

人工智慧的累積影響

人工智慧正日益成為乳房攝影影像和病理工作流程中一股不可忽視的力量。獲得FDA註冊的AI/ML醫療設備主要集中在放射科，乳房攝影影像工具也擴大用於輔助檢測、分流、乳房密度評估、影像品質審查和品管。在病理學領域，AI驅動的影像分析對於數位切片審查、工作流程優先排序和確保結果可重複性也變得越來越重要。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

在亞太地區，隨著篩檢參與率、診斷影像能力和腫瘤基礎設施的提升，中國、印度、日本、韓國和澳洲的市場正在擴張。儘管公眾意識的提高、私人醫療保健的擴張以及政府主導的癌症防治舉措推動了市場成長，但農村地區的醫療服務可及性、成本效益以及病理人員短缺仍然是該地區部分地區面臨的重大挑戰。日本、韓國和澳洲擁有成熟的影像系統，而中國和印度則繼續向其龐大的人口推廣乳房X光檢查、超音波、切片檢查和病理服務。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團與北約

東協市場的特點是癌症防治意識不斷增強、都市區診斷中心不斷擴張以及公共篩檢覆蓋範圍不均，這催生了對價格合理的乳房X光攝影X光檢查、超音波、切片檢查和病理服務的需求。海灣合作理事會（GCC）國家正在投資建立現代化腫瘤生態系統、數位化醫院和國家篩檢舉措，從而推動了三級醫療機構對高品質影像、綜合診斷和人工智慧驅動的工作流程的需求。

主要國家乳癌診斷趨勢

美國仍然是創新和技術應用領域的領先中心。美國癌症協會估計，到2024年，美國女性新增侵襲性乳癌病例將超過31萬例，而乳房X光檢查、切片檢查、病理檢查、免疫組化、基因組檢測和人工智慧影像工具等技術已被廣泛應用。在加拿大，系統性篩檢和各省之間公平的醫療服務取得受到重視。同時，在墨西哥和巴西，儘管對影像和病理服務的需求不斷成長，但在篩檢參與率、反應時間和獲得腫瘤專科護理方面仍然存在區域差異。

為行業領導者提供的實用建議

產業領導者應優先考慮經臨床檢驗的解決方案，以縮短從篩檢發現異常觀察到最終確診的時間。投資應集中於可互通的影像技術、切片檢查引導、數位病理檢測、生物標記檢測以及人工智慧工具，這些技術應在檢測準確性、工作流程效率、可重複性或患者預後方面展現出可衡量的改進。

調查方法

本研究採用三角測量法，結合了檢驗的二手資訊、專家一手資訊和分析檢驗。主要參考文獻包括世界衛生組織、國際癌症研究機構/全球癌症聯盟、國家癌症登記處、美國疾病管制與預防中心、美國癌症協會、美國預防服務工作小組、美國食品藥物管理局醫療設備資料庫、經合組織健康資料、專業學會指南以及公共保險報銷、採購和監管的資訊。

結論

乳癌診斷正進入一個新階段，其特點是早期發現、精準的生物標記檢測、數位化工作流程的整合以及負責任的人工智慧技術的應用。能夠提高診斷可靠性、減少延誤並將影像學、病理學、分子檢測和治療方案製定相結合的技術，將創造最大的商業機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章乳癌診斷市場：依產品/服務分類

  • 裝置
    • 切片檢查設備
    • 影像系統
    • 序列器
  • 耗材和試劑
    • 檢測試劑盒
    • 玻片和染色試劑
  • 軟體
    • 工作流程資訊學
    • 數據分析軟體
  • 服務
    • 諮詢
    • 安裝/維護

第8章乳癌診斷市場：依技術分類

  • 切片檢查
    • 針刺切片
    • 手術切片檢查
  • 組織病理學
    • 免疫組織化學
    • 常規組織學
  • 診斷影像
    • 乳房X光檢查
    • 磁振造影（MRI）
    • 超音波
  • 分子診斷
    • 螢光原位雜合反應（FISH）
    • 次世代定序（NGS）
    • 基於PCR的

第9章乳癌診斷市場：依生物標記類型分類

  • BRCA
  • ER/PR
  • HER2
  • Ki-67

第10章：乳癌診斷市場：依檢體類型分類

  • 血
  • 血清
  • 組織

第11章乳癌診斷市場：依臨床應用案例分類

  • 大規模健康檢查
  • 確診
  • 風險分層
  • 治療方案
  • 治療監測
  • 復發監測

第12章乳癌診斷市場：依最終用戶分類

  • 癌症研究中心
  • 診斷檢查室
  • 醫院和診所

第13章乳癌診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章乳癌診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章乳癌診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Hologic, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Koninklijke Philips NV
  • FUJIFILM Holdings Corporation
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Agilent Technologies, Inc.
  • Cardinal Health, Inc.
  • 4D Path Inc.
  • AstraZeneca PLC
  • Biodesix, Inc.
  • Exact Sciences Corporation
  • Fluxion Biosciences Inc. by Cell Microsystems
  • NanoString Technologies, Inc.
  • NeoGenomics Laboratories
  • Olea Medical
  • OncoGenomX
  • Planmed Oy
  • Quest Diagnostics Incorporated
  • Todos Medical Ltd.
  • TransMed7, LLC
Product Code: MRR-A26E0E57405A

The Breast Cancer Diagnostics Market is projected to grow by USD 11.54 billion at a CAGR of 8.03% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.71 billion
Estimated Year [2026] USD 7.24 billion
Forecast Year [2032] USD 11.54 billion
CAGR (%) 8.03%

Breast cancer diagnostics is moving from episodic detection toward integrated, risk-based care that combines screening mammography, ultrasound, MRI, biopsy, histopathology, immunohistochemistry, genomic assays, and digital pathology. The clinical urgency is clear: the World Health Organization reported about 2.3 million women diagnosed with breast cancer and roughly 670,000 deaths worldwide in 2022, making timely detection and accurate diagnosis central to cancer control.

For industry leaders, opportunity is tied to earlier detection, faster confirmation, and more precise treatment selection. Demand is strongest where organized screening, reimbursement, pathology capacity, and oncology infrastructure align, making diagnostic accuracy, workflow efficiency, access expansion, and evidence-based care pathways central competitive differentiators.

Transformative Shifts in Breast Cancer Diagnostics

The landscape is being reshaped by three structural shifts: expanded screening access, precision oncology, and digitally enabled diagnostics. Digital breast tomosynthesis is improving lesion visualization, while MRI and ultrasound remain important for dense breast tissue, high-risk patients, and diagnostic follow-up. Updated screening guidance in several countries is also strengthening attention on risk stratification, breast density, and timely diagnostic workup after abnormal findings.

At the same time, biomarker testing for ER, PR, HER2, Ki-67, and multigene recurrence risk has made diagnostics essential to therapy selection. Laboratories and imaging providers are investing in interoperability, quality assurance, standardized reporting, and faster turnaround as health systems prioritize earlier-stage detection, multidisciplinary decision-making, and patient-centered care pathways.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a measurable force in breast imaging and pathology workflows. FDA-listed AI/ML-enabled medical devices are concentrated heavily in radiology, and breast imaging tools are increasingly used for detection support, triage, breast density assessment, image quality review, and quality control. In pathology, AI-assisted image analysis is gaining relevance for digital slide review, workflow prioritization, and reproducibility support.

Evidence is advancing. The MASAI randomized screening trial reported that AI-supported mammography detected more cancers while reducing screen-reading workload, supporting the case for AI as an assistive technology rather than a standalone replacement for radiologists. Adoption will depend on clinical validation, bias monitoring across population groups, cybersecurity, reimbursement, and integration with PACS, RIS, laboratory information systems, and electronic health records.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia increase screening participation, diagnostic imaging capacity, and oncology infrastructure. Growth is supported by rising awareness, expanding private healthcare, and government-led cancer control initiatives, although rural access, affordability, and pathology workforce gaps remain significant in parts of the region. Japan, South Korea, and Australia have mature imaging systems, while China and India continue to scale mammography, ultrasound, biopsy, and pathology services for large populations.

North America leads in advanced mammography, molecular diagnostics, image-guided biopsy, and AI-enabled workflows, supported by reimbursement, clinical guidelines, cancer registries, and strong cancer center networks. Europe benefits from organized screening programs, quality assurance standards, and broad adoption of pathology and biomarker testing across many health systems. Latin America shows rising demand for breast imaging and confirmatory diagnostics, but access remains uneven between urban centers and underserved regions. The Middle East is investing in specialty hospitals, screening campaigns, and imaging networks, whereas Africa faces late-stage presentation, limited mammography density, and pathology bottlenecks that make scalable, cost-effective diagnostics essential.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7 & NATO

ASEAN markets are characterized by rising cancer awareness, expanding urban diagnostic centers, and uneven public screening coverage, creating demand for affordable mammography, ultrasound, biopsy, and pathology services. GCC countries are investing in modern oncology ecosystems, digital hospitals, and national screening initiatives, making premium imaging, integrated diagnostics, and AI-supported workflows increasingly attractive in tertiary care settings.

The European Union benefits from coordinated cancer policy, population-based screening recommendations, conformity assessment standards, and cross-border evidence generation. BRICS markets combine large patient populations with expanding healthcare infrastructure, making access, price-performance, training, and localized service models important for adoption. G7 countries lead in reimbursement depth, guideline-based screening, digital pathology readiness, AI evaluation, and precision diagnostics. NATO member markets add resilience, cybersecurity, data governance, and supply continuity considerations to procurement decisions for critical diagnostic technologies.

Key Country Insights in Breast Cancer Diagnostics

The United States remains a major innovation and adoption hub, with the American Cancer Society estimating more than 310,000 new invasive breast cancer cases in women in 2024 and strong use of mammography, biopsy, pathology, immunohistochemistry, genomic testing, and AI-enabled imaging tools. Canada emphasizes organized screening and equitable provincial access, while Mexico and Brazil show growing demand for diagnostic imaging and pathology services but continue to face regional disparities in screening participation, diagnostic turnaround, and access to specialty oncology care.

The United Kingdom, Germany, France, Italy, and Spain rely on established screening and pathology systems, supported by national or regional breast screening programs, multidisciplinary cancer care, and broad biomarker testing. Russia maintains demand for imaging modernization and oncology infrastructure development. China and India represent scale-driven growth as awareness, hospital investment, and cancer programs expand, while access gaps persist between major cities and lower-resource settings. Japan and South Korea emphasize high-quality imaging, health checkup culture, and technology adoption, and Australia benefits from organized screening, strong clinical governance, and established breast cancer care pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated solutions that shorten the time from abnormal screen to confirmed diagnosis. Investment should focus on interoperable imaging, biopsy guidance, pathology digitization, biomarker testing, and AI tools that demonstrate measurable gains in detection accuracy, workflow efficiency, reproducibility, or patient outcomes.

Commercial strategies must align with local reimbursement, screening policy, regulatory expectations, data governance, and workforce realities. Vendors should build evidence packages for regulators and payers, support training for radiologists, pathologists, technologists, and laboratory teams, and develop tiered offerings for high-income, emerging, and resource-constrained markets without compromising quality assurance or patient safety.

Research Methodology

This research applies a triangulated methodology using verified secondary sources, primary expert inputs, and analytical validation. Core references include WHO, IARC/GLOBOCAN, national cancer registries, CDC, American Cancer Society, USPSTF, FDA device databases, OECD health data, professional society guidelines, and public reimbursement, procurement, and regulatory information.

The research process evaluates epidemiology, screening policy, technology adoption, regulatory pathways, payer dynamics, clinical workflow, competitive positioning, and regional healthcare infrastructure. Findings are cross-checked to avoid unsupported projections and to ensure that market interpretation remains grounded in documented clinical, regulatory, and healthcare system evidence.

Conclusion

Breast cancer diagnostics is entering a new phase defined by earlier detection, precision biomarker testing, digital workflow integration, and responsible AI adoption. The strongest opportunities will emerge where technologies improve diagnostic confidence, reduce delays, and connect imaging with pathology, molecular testing, and treatment planning.

As disease burden remains high worldwide, stakeholders that combine clinical evidence, access strategy, regulatory readiness, data security, and scalable implementation will be best positioned to lead in breast cancer diagnostics while supporting better outcomes across diverse healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Breast Cancer Diagnostics Market, by Offering

  • 7.1. Instruments
    • 7.1.1. Biopsy Devices
    • 7.1.2. Imaging Systems
    • 7.1.3. Sequencers
  • 7.2. Consumables & Reagents
    • 7.2.1. Assay Kits
    • 7.2.2. Slides & Staining Reagents
  • 7.3. Software
    • 7.3.1. Workflow Informatics
    • 7.3.2. Data Analysis Software
  • 7.4. Services
    • 7.4.1. Consulting
    • 7.4.2. Installation & Maintenance

8. Breast Cancer Diagnostics Market, by Technology

  • 8.1. Biopsy
    • 8.1.1. Needle Biopsy
    • 8.1.2. Surgical Biopsy
  • 8.2. Histopathology
    • 8.2.1. Immunohistochemistry
    • 8.2.2. Routine Histology
  • 8.3. Imaging
    • 8.3.1. Mammography
    • 8.3.2. Magnetic Resonance Imaging (MRI)
    • 8.3.3. Ultrasound
  • 8.4. Molecular Diagnostics
    • 8.4.1. Fluorescence In Situ Hybridization (FISH)
    • 8.4.2. Next-Generation Sequencing (NGS)
    • 8.4.3. PCR-Based

9. Breast Cancer Diagnostics Market, by Biomarker Type

  • 9.1. BRCA
  • 9.2. ER/PR
  • 9.3. HER2
  • 9.4. Ki-67

10. Breast Cancer Diagnostics Market, by Sample Type

  • 10.1. Blood
  • 10.2. Serum
  • 10.3. Tissue

11. Breast Cancer Diagnostics Market, by Clinical Use Case

  • 11.1. Population Screening
  • 11.2. Diagnostic Confirmation
  • 11.3. Risk Stratification
  • 11.4. Therapy Selection
  • 11.5. Treatment Monitoring
  • 11.6. Recurrence Surveillance

12. Breast Cancer Diagnostics Market, by End User

  • 12.1. Cancer Research Centers
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Clinics

13. Breast Cancer Diagnostics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Breast Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Breast Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Hologic, Inc.
  • 17.2. F. Hoffmann-La Roche Ltd.
  • 17.3. GE HealthCare Technologies Inc.
  • 17.4. Siemens Healthineers AG
  • 17.5. Thermo Fisher Scientific Inc.
  • 17.6. Koninklijke Philips N.V.
  • 17.7. FUJIFILM Holdings Corporation
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. Illumina, Inc.
  • 17.10. Danaher Corporation
  • 17.11. Abbott Laboratories
  • 17.12. Becton, Dickinson and Company
  • 17.13. Agilent Technologies, Inc.
  • 17.14. Cardinal Health, Inc.
  • 17.15. 4D Path Inc.
  • 17.16. AstraZeneca PLC
  • 17.17. Biodesix, Inc.
  • 17.18. Exact Sciences Corporation
  • 17.19. Fluxion Biosciences Inc. by Cell Microsystems
  • 17.20. NanoString Technologies, Inc.
  • 17.21. NeoGenomics Laboratories
  • 17.22. Olea Medical
  • 17.23. OncoGenomX
  • 17.24. Planmed Oy
  • 17.25. Quest Diagnostics Incorporated
  • 17.26. Todos Medical Ltd.
  • 17.27. TransMed7, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BREAST CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPSY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPSY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SEQUENCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEQUENCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SEQUENCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ASSAY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASSAY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ASSAY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SLIDES & STAINING REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SLIDES & STAINING REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SLIDES & STAINING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL WORKFLOW INFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL WORKFLOW INFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL WORKFLOW INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DATA ANALYSIS SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DATA ANALYSIS SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DATA ANALYSIS SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONSULTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONSULTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONSULTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INSTALLATION & MAINTENANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INSTALLATION & MAINTENANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INSTALLATION & MAINTENANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEEDLE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEEDLE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEEDLE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SURGICAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SURGICAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SURGICAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HISTOPATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HISTOPATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HISTOPATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ROUTINE HISTOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ROUTINE HISTOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ROUTINE HISTOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MAMMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MAMMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MAMMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PCR-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PCR-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PCR-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRCA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRCA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRCA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ER/PR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ER/PR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ER/PR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HER2 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HER2 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HER2 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL KI-67 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL KI-67 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL KI-67 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL POPULATION SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL POPULATION SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL POPULATION SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DIAGNOSTIC CONFIRMATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIAGNOSTIC CONFIRMATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DIAGNOSTIC CONFIRMATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RISK STRATIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RISK STRATIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RISK STRATIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL THERAPY SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL THERAPY SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL THERAPY SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL TREATMENT MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TREATMENT MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RECURRENCE SURVEILLANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RECURRENCE SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RECURRENCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 246. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 248. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 250. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 254. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 258. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 291. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 293. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 294. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 295. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 297. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 299. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 303. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 306. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 308. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 309. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 310. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 312. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 314. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 315. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 318. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 335. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 337. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 339. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 340. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 341. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 342. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 343. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 344. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 345. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 346. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 348. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL USE CASE, 2018-2032 (USD MILLION)
  • TABLE 349. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 350. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 351. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 352. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 353. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 354. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 355. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERVICE